… We report the effects of apixaban versus acetylsalicylic acid (ASA) in older patients (≥75
years … , it difficult to justify the use of aspirin in elderly patients with AF, if apixaban is available. …

… In summary, it seems reasonable to use NOACs for elderly patients with AF instead … elderly
patients compared with VKA on apixaban followed by edoxaban, whereas in elderly patients, …

… versus warfarin on HCRU and costs among elderly NVAF patients. The results of the study
show that elderly NVAF patients who initiated apixaban significantly differed in many patient …

… dose (in the present study, ≥86 ng/mL) could be a tool for identifying those with a high risk
of bleeding among elderly patients with AF, although a high Api-AXA value itself does not …

… The apixaban CL R tended to be lower in elderly subjects (0.45 L/h) than in young subjects
(0.63 L/h) and lower in female subjects (0.46 L/h) than in male subjects (0.62 L/h); these …

… of the on-label reduced dose apixaban in >1700 elderly AF patients, supporting the conclusions
shown in the ARISTOTLE subanalysis for the elderly patients.14 Since underdosing of …

… However, data from phase III clinical trials on atrial fibrillation overall indicate that apixaban
and edoxaban in elderly patients are associated with the highest reduction of extracranial …

… in elderly patients with atrial fibrillation (AF) in a real-world population. Methods We identified
all anticoagulant-naive initiators of warfarin, dabigatran, rivaroxaban and apixaban for the …

… studies with elderly participants have shown that apixaban is … safety of apixaban is consistent
among various groups of patients, … Elderly patients with AF and VTE are at elevated risk of …

… was observed in older AF patients, as opposed to lower risks for apixaban and edoxaban. …
of NOACs versus VKAs in elderly atrial fibrillation patients ≥75 years old. Api 5/2.5, …